StockData
Summit Therapeutics Inc. logo

Summit Therapeutics Inc. (SMMT) stock

SMMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$10.50−0.17 (-1.59%)

Close on Nov 18, 2026Market cap $8.38BP/E –Yield –

Summit Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Summit Therapeutics's price to sales ratio was 395.2× on Apr 28, 2023, against 4.6× a year earlier. Over the last 4 years it ranged from 0.4× to 395.2×, with a median of 1.9×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2023Apr 28, 2023395.2×+226.8
2022Nov 30, 2022168.5×+163.9
2021Dec 31, 20214.6×+3.2
2020Dec 31, 20201.4×+0.9
2019Dec 31, 20190.5×–

More Summit Therapeutics figures

See a number that looks wrong?